Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.For development of Raf kinase inhibitor in treatment of cancer
Subscribe to our email newsletter
Sunesis has received a $1.5 million milestone payment from Biogen Idec for the selection of a Raf kinase inhibitor development candidate. It is intended for the treatment of cancer.
Biogen Idec is currently conducting IND-enabling GLP preclinical work with the Raf kinase development candidate.
In August 2004, the companies entered into a collaboration to discover and develop small molecule cancer therapeutics targeting kinases.
Daniel Swisher, CEO of Sunesis, said: While our internal efforts are focused on the successful development of voreloxin, we are extremely pleased by the continued progress being made by Biogen Idec to advance a Raf kinase inhibitor toward the clinic.
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, for the treatment of solid and hematologic cancers.